Neurogastroenterology is a subspecialty encompassing relations of the nervous system to the gastrointestinal tract. The central concept is emergence of whole organ behavior from coordinated activity of the musculature, mucosal epithelium and blood vasculature. Behavior of each effector is determined by the enteric nervous system (ENS). The ENS is a minibrain positioned close to the effectors it controls. ENS neurophysiology is in the framework of neurogastroenterology.
The digestive tract is recognized as the largest lymphoid organ in the body together with a unique compliment of mast cells. In its position at the "dirtiest" of interfaces between the body and outside world, the mucosal immune system encounters food antigens, bacteria, parasites, viruses and toxins. Epithelial barriers are insufficient to exclude fully the antigenic load thereby allowing chronic challenges to the immune system. Our observations in antigen-sensitized animals document direct communication between the mucosal immune system and ENS. Communication is functional and results in adaptive responses to circumstances with the lumen that are threatening to the functional integrity of the whole animal. Communication is paracrine and incorporates specialized sensing functions of mast cells for specific antigens together with the capacity of the ENS for intelligent interpretation of the signals. Immuno-neural integration progresses sequentially beginning with immune detection followed by signal transfer to the ENS followed by neural interpretation and then selection of a neural program with coordinated mucosal secretion and a propulsive motor event that quickly clears the threat from the intestinal lumen. Operation of the defense program evokes symptoms of cramping abdominal pain, fecal urgency and watery diarrhea. Our approaches to immuno-ENS interactions merge the disciplines of mucosal immunology ENS neurophysiology into the realm of neurogastroenterology. The intestinal Na + /glucose cotransporter, SGLT1, is the major route for the transport of dietary sugars from the lumen of the intestine into enterocytes. Regulation of this protein is essential for the provision of glucose to the body and avoidance of malabsorption. Data produced in various laboratories have suggested that the intestinal lumenal sugar concentration, the gut hormone, GLP-2, and the enteric nervous system participate in pathways regulating SGLT1 expression. To this end, it has been shown that i) expression of SGLT1 is upregulated in response to increased dietary sugars, ii) the serosal application of GLP-2 enhances SGLT1 expression, iii) raised lumenal glucose concentrations in the ileum results in SGLT1 upregulation in more proximal regions and iv) the upregulation of SGLT1 in response to high lumenal glucose is only achieved in intact mucosa and not in isolated enterocytes. However detailed network of pathways by which the lumenal sugar, gut hormones and the enteric nervous system interact to regulate SGLT1 expression has not been known. Experimental evidence in our laboratory has shown that the intestinal glucose sensor, the taste receptor1 subunit heterodimers, T1R2+T1R3, expressed on the luminal membrane of endocrine cells, senses lumenal glucose concentration. Lumenal glucose when above a threshold activates in endocrine cells, a signalling pathway involving T1R2+T1R3, the transducer G-protein, gustducin, and other signalling elements, resulting in secretion of GLP-1, GLP-2 and GIP. Binding of GLP-2 to its receptor on enteric neurons elicits a neuronal response which is transmitted to subepithelial regions evoking the release of a neuropeptide. Binding of the neuropeptide to its receptor on the basolateral membrane of absorptive enterocytes enhances intracellular cAMP, thereby increasing the stability of SGLT1 mRNA and levels of functional SGLT1 protein. The identification of molecular and cellular processes controlling SGLT1 expression will assist recognition of targets for modulating the capacity of the gut to absorb dietary sugars. This has important nutritional and clinical implications. The regulation of nutrient absorptive capacity is a critical factor in the normal growth and development of an infant. This is especially important following surgical resection; the process of adaptation, or upregulation of nutrient transport capacity is the physiologic process which allows patients to transition to enteral feeding. The specific mechanisms which control this are still relatively poorly understood. Many actions of the entero-endocrine hormone, Glucagon-like Peptide 2, suggest that it may be a key regulator both in regulating physiological nutrient absorptive capacity and the process of adaptative upregulation of nutrient absorption following resection. This talk will review the biology of GLP-2 including the production in the L cell, regulation of GLP-2 release, sites of action, which include the enteric neurons, and pericryptal myofibroblast, and the effects on the intestinal mucosa. We will examine ontogeny of this system in the developing human infant and the evidence that GLP-2 is pivotal in the regulation of adaptation, with the implications for clinical practice.
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